FDA Extends PDUFA Date for Obeticholic Acid for the Treatment of PBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- AI stocks lift Wall St as oil falls, Treasury yields decline
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
- Novo Nordisk shares drop as investor event disappoints
Consensus Needs to Come Down on Intercept (ICPT) after FDA Review is Extended - Leerink
December 18, 2015 8:44 AM ESTLeerink Partners analyst, Joseph Schwartz noted that Intercept Pharmaceuticals (NASDAQ: ICPT) announced that the FDA has extended the PDUFA date for its priority review application of Obeticholic acid (OCA) in primary biliary cirrhosis/ cholangitis (PBC) by 3 mos. to May 29, 2016. ICPT stated that FDA had requested additional information, to which ICPT has... More
FDA Pushed Back Intercept Pharma's (ICPT) PDUFA Date; Seeks More Data - Baird Maintains Outperform
December 18, 2015 7:41 AM ESTBaird maintained an Outperform rating and $346.00 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) following the company's announcement that the FDA pushed out its Prescription Drug User Fee Act (PDUFA) date for the priority review of obeticholic acid (OCA) in primary biliary cholangitis (PBC). The... More
